BioHarvest Sciences Inc has authorized a share repurchase program to buy back up to 5% of its outstanding shares, totaling a maximum of 1,133,392 shares over 12 months. The company believes its current market price undervalues its business and growth potential. CEO Dr. Zaki Rakib highlighted the company's evolution into a technology-driven firm with a proprietary Botanical Synthesis platform, expanding beyond its VINIA product to develop high-value plant-derived molecules. This buyback aims to effectively allocate capital and support the company’s expanding commercial programs in natural sweeteners, rare fragrances, and other compounds.
BioHarvest Sciences' share buyback announcement is presented here with relevant market data from Pluang's Health sector. For readers following health stocks, as of Sep 29, 2026 19:14 WIB, out of 100 priced US health-sector stocks tradable on Pluang, 50 rose and 41 fell. Notable movers include TXG (10X Genomics Inc) at USD 89.73 with a 1-day change of +1.39% and balanced Pluang order activity (49% Sell / 51% Buy), WGS (GeneDx Holdings Corp) at USD 84.75 down 1.37% with 100% Buy order activity, and RXRX (Recursion Pharmaceuticals Inc) at USD 3.75 up 1.35% with 100% Buy order activity and typical hold times ranging from 19 to 92 days.
Netflix shares rose 1.5% after Deutsche Bank upgraded the stock from Hold to Buy, citing recent price declines as a buying opportunity and stronger international trends. However, other analysts remain cautious, with Wells Fargo downgrading Netflix to...
Cytokinetics' CEO Robert I. Blum and other executives have recently sold large amounts of company stock, with Blum selling nearly 105,000 shares in total, including a major block under a pre-arranged trading plan. This insider selling occurs while th...
Carnival Corporation reported strong quarterly results with earnings per share of $1.43 and net income of $1.92 billion, surpassing analyst expectations. The company achieved record revenue of $8.44 billion, driven by growing consumer interest in cru...
FactSet is set to report strong Q3 earnings with an expected EPS of $4.35 and revenue around $629.83 million, reflecting a 5.3% increase from last year. The company benefits from high demand for AI-related products, expanded client base, and effectiv...
Jefferies Financial Group reported robust Q3 results with earnings per share of $1.09, beating analyst estimates and last year's $1.05. Revenue rose to $2.22 billion, driven by record banking revenue, surpassing expectations. Net earnings increased t...
